Product image of Mingerlan (Tamsulosin Hydrochloride, Solifenacin Succinate) supplied by GNH India

Mingerlan

Active Ingredient:
Tamsulosin Hydrochloride, Solifenacin Succinate
Origin:
EU

Mingerlan (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredient in Mingerlan, is an alpha‑1 adrenergic antagonist combined with an antimuscarinic, presented as an oral tablet for oral administration. It targets smooth muscle tone in the prostate and detrusor muscle activity in the bladder, providing symptom relief for benign prostatic hyperplasia and overactive bladder in adult patients.

GNH India supplies Mingerlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets through reliable logistics.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mingerlan combines an alpha‑1 antagonist and an antimuscarinic to treat lower urinary tract disorders.

  • Benign prostatic hyperplasia (BPH): improves urinary flow and reduces nocturia, hesitancy, and incomplete emptying.
  • Overactive bladder (OAB): decreases urgency, frequency, and urge incontinence episodes.
  • Urinary retention secondary to BPH: facilitates bladder emptying and reduces residual volume.

How It Works

  • Tamsulosin selectively blocks alpha‑1A adrenergic receptors on prostatic smooth muscle, lowering urethral resistance, while Solifenacin antagonizes muscarinic M3 receptors in the bladder detrusor muscle, suppressing involuntary contractions and improving storage symptoms.

Side Effects

Mingerlan may cause a range of adverse reactions.

Common Side Effects

  • Dizziness: transient light‑headedness, especially on standing.
  • Dry mouth: reduced salivation leading to throat discomfort.
  • Constipation: slowed gastrointestinal motility.
  • Headache: mild to moderate pressure sensation.
  • Orthostatic hypotension: drop in blood pressure upon standing.
  • Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

  • Priapism: prolonged painful erection requiring urgent care.
  • Severe urinary retention: inability to void, may need catheterisation.
  • Allergic reactions: rash, swelling, or anaphylaxis.
  • QT interval prolongation: cardiac rhythm disturbance in susceptible patients.

Precautions & Warnings

Before prescribing Mingerlan, clinicians should consider several safety measures.

  • Monitor blood pressure: watch for hypotension, especially after the first dose.
  • Assess urinary flow: ensure no acute retention before initiating therapy.
  • Evaluate hepatic function: dose adjustment may be needed in severe impairment.
  • Caution in narrow‑angle glaucoma: antimuscarinic effect can increase intra‑ocular pressure.
  • Avoid use in severe hepatic impairment: risk of accumulation.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Mingerlan can interact with other medicines, requiring careful review.

Major Interactions (Avoid)

  • Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
  • Other alpha‑blockers (e.g., doxazosin): additive hypotensive effect.
  • Concurrent antimuscarinics (e.g., oxybutynin): risk of excessive anticholinergic burden.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.

  • Diuretics: enhanced orthostatic hypotension.
  • Antihistamines or tricyclic antidepressants: increase anticholinergic side effects.

Frequently Asked Questions

Mingerlan is prescribed for adult patients with benign prostatic hyperplasia (BPH) to improve urinary flow and reduce symptoms, as well as for overactive bladder (OAB) to lessen urgency, frequency, and urge incontinence. It may also be used when BPH leads to urinary retention.

Tamsulosin blocks alpha‑1A receptors in prostatic smooth muscle, relaxing the prostate and decreasing urethral resistance. Solifenacin blocks muscarinic M3 receptors in the bladder detrusor muscle, reducing involuntary contractions. Together they address both obstructive and storage urinary symptoms.

The specific dose of Mingerlan is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Mingerlan in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Mingerlan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mingerlan combines an alpha‑1 blocker and an antimuscarinic in a single tablet, offering convenience over separate prescriptions. Compared with monotherapy, it may provide broader symptom control but shares similar safety profiles. Choice of therapy should be individualized based on symptom pattern and patient tolerance.

Mingerlan should be stored at room temperature, below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near a heat source.

Mingerlan is taken orally, usually once daily with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber.

Serious risks include priapism, severe urinary retention, allergic reactions such as rash or anaphylaxis, and QT interval prolongation in susceptible individuals. Patients should seek immediate medical attention if they experience prolonged erection, inability to urinate, or signs of an allergic reaction.

Mingerlan is contraindicated in patients with known hypersensitivity to tamsulosin, solifenacin, or any excipients, as well as in those with severe hepatic impairment. Caution is advised for patients with narrow‑angle glaucoma, severe hypotension, or a history of priapism.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tamsulosin Hydrochloride, Solifenacin Succinate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT